ATE497775T1 - Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) - Google Patents

Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)

Info

Publication number: ATE497775T1
Authority: AT; Austria
Prior art keywords: hcv; cyclosporine; hepatitis; treatment; combination
Prior art date: 2004-07-14

Application number

AT05759733T

Other languages

English (en)

Inventor

Catherine Cornu-Artis

Guylaine Vachon

Yoko Uryuhara

Kazuo Asakawa

Reinhild Elisabeth Mertes

Shinsyou Yoshiba

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-14

Filing date

2005-07-13

Publication date

2011-02-15

2005-07-13 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2011-02-15 Application granted granted Critical

2011-02-15 Publication of ATE497775T1 publication Critical patent/ATE497775T1/de

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 3
108010036949 Cyclosporine Proteins 0.000 title abstract 2
102000014150 Interferons Human genes 0.000 title abstract 2
108010050904 Interferons Proteins 0.000 title abstract 2
229960001265 ciclosporin Drugs 0.000 title abstract 2
229930182912 cyclosporin Natural products 0.000 title 1
208000006454 hepatitis Diseases 0.000 title 1
231100000283 hepatitis Toxicity 0.000 title 1
229940047124 interferons Drugs 0.000 title 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
229940079322 interferon Drugs 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
229920003169 water-soluble polymer Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT05759733T 2004-07-14 2005-07-13 Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv) ATE497775T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04016583		2004-07-14
PCT/EP2005/007633 WO2006005610A1 (en)	2004-07-14	2005-07-13	Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)

Publications (1)

Publication Number	Publication Date
ATE497775T1 true ATE497775T1 (de)	2011-02-15

Family

ID=34972493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05759733T ATE497775T1 (de)	2004-07-14	2005-07-13	Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)

Country Status (15)

Country	Link
US (1)	US7671017B2 (de)
EP (1)	EP1778272B1 (de)
JP (1)	JP2008506648A (de)
KR (1)	KR20070036175A (de)
CN (1)	CN1984671A (de)
AT (1)	ATE497775T1 (de)
AU (1)	AU2005261868B2 (de)
BR (1)	BRPI0513370A (de)
CA (1)	CA2573207C (de)
DE (1)	DE602005026294D1 (de)
ES (1)	ES2359925T3 (de)
MX (1)	MX2007000503A (de)
PL (1)	PL1778272T3 (de)
RU (1)	RU2394589C2 (de)
WO (1)	WO2006005610A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2006524232A (ja)	2003-03-17	2006-10-26	アルバニーモレキュラーリサーチインコーポレーティッド	新規サイクロスポリン
JP2008514701A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	シクロスポリンアルキン類似体およびそれらの薬学的使用
EP1804823A4 (de)	2004-09-29	2010-06-09	Amr Technology Inc	Neue cyclosporin-analoga und ihre pharmazeutischen anwendungen
US7196161B2 (en)	2004-10-01	2007-03-27	Scynexis Inc.	3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7361636B2 (en)	2004-10-06	2008-04-22	Amr Technology, Inc.	Cyclosporin alkynes and their utility as pharmaceutical agents
BRPI0616476A2 (pt)	2005-09-30	2011-06-21	Scynexis Inc	uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en)	2005-09-30	2012-12-11	Scynexis, Inc.	Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
US7696165B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en)	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
ATE502633T1 (de)	2006-05-19	2011-04-15	Scynexis Inc	Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
US7576057B2 (en)	2006-11-20	2009-08-18	Scynexis, Inc.	Cyclic peptides
US9090671B2 (en)	2008-06-06	2015-07-28	Scynexis, Inc.	Macrocyclic peptides
EP2337583A1 (de) *	2008-09-17	2011-06-29	Boehringer Ingelheim International GmbH	Kombination aus hcv-ns3-proteasehemmer mit interferon und ribavirin
WO2010069809A1 (en) *	2008-12-18	2010-06-24	F. Hoffmann-La Roche Ag	Biomarkers for hcv treatment response
EP2376524B1 (de)	2008-12-31	2017-03-15	Cypralis Limited	Derivate von cyclosporin a
SG173180A1 (en)	2009-01-30	2011-09-29	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
AR075584A1 (es) *	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
BR112012010110A2 (pt)	2009-10-30	2019-09-24	Boehringer Ingelheim Int	regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
BR112012033022A2 (pt)	2010-06-24	2016-12-20	Genosciense Pharma Sas	tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
WO2012176149A1 (en)	2011-06-23	2012-12-27	Panmed Ltd.	Treatment of hepatitis c virus
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
CN104023726A (zh)	2011-10-21	2014-09-03	艾伯维公司	用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
CA2811203C (en)	2011-10-21	2015-05-05	Abbvie Inc.	Methods for treating hcv
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
WO2014122537A2 (en)	2013-02-05	2014-08-14	Genoscience Sa	Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
SG11201601274QA (en)	2013-08-26	2016-03-30	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c
WO2016073480A1 (en)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Novel cyclosporin analogues for preventing or treating hepatitis c infection
JP7129703B2 (ja)	2016-04-28	2022-09-02	エモリーユニバーシティー	アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
ATE148469T1 (de)	1990-11-02	1997-02-15	Sandoz Ag	Zyklosporine
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US5858389A (en) *	1996-08-28	1999-01-12	Shaker H. Elsherbini	Squalene is an antiviral compound for treating hepatitis C virus carriers
FR2757521B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
US20030216303A1 (en) *	1998-03-06	2003-11-20	Michael Ambuhl	Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en)	1998-06-02	1998-07-29	Ciba Geigy Ag	Organic compounds
US6136835A (en) *	1999-05-17	2000-10-24	The Procter & Gamble Company	Methods of treatment for viral infections
AR031010A1 (es)	2000-10-19	2003-09-03	Fujisawa Pharmaceutical Co	Una composicion farmaceutica, util para inhibir el dano celular
AU2003223913A1 (en) *	2002-04-05	2003-10-20	Viromics Gmbh	Agents for treating less thanigreater thanflaviviridaeless than/igreater than infections
GB2391471B (en) *	2002-08-02	2005-05-04	Satishchandra Punambhai Patel	Pharmaceutical compositions
GB0320638D0 (en) *	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
UA88484C2 (ru)	2004-10-01	2009-10-26	Дебиофарм Са	ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
CA2587793A1 (en)	2004-12-23	2006-07-06	Novartis Ag	Compositions for hcv treatment

2005
- 2005-07-13 BR BRPI0513370-0A patent/BRPI0513370A/pt not_active IP Right Cessation
- 2005-07-13 MX MX2007000503A patent/MX2007000503A/es active IP Right Grant
- 2005-07-13 US US11/572,110 patent/US7671017B2/en not_active Expired - Fee Related
- 2005-07-13 DE DE602005026294T patent/DE602005026294D1/de not_active Expired - Lifetime
- 2005-07-13 KR KR1020077003409A patent/KR20070036175A/ko not_active Ceased
- 2005-07-13 PL PL05759733T patent/PL1778272T3/pl unknown
- 2005-07-13 AT AT05759733T patent/ATE497775T1/de active
- 2005-07-13 AU AU2005261868A patent/AU2005261868B2/en not_active Ceased
- 2005-07-13 JP JP2007520752A patent/JP2008506648A/ja active Pending
- 2005-07-13 EP EP05759733A patent/EP1778272B1/de not_active Expired - Lifetime
- 2005-07-13 RU RU2007105354/14A patent/RU2394589C2/ru not_active IP Right Cessation
- 2005-07-13 WO PCT/EP2005/007633 patent/WO2006005610A1/en not_active Ceased
- 2005-07-13 CN CNA2005800237603A patent/CN1984671A/zh active Pending
- 2005-07-13 ES ES05759733T patent/ES2359925T3/es not_active Expired - Lifetime
- 2005-07-13 CA CA2573207A patent/CA2573207C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2008506648A (ja)	2008-03-06
EP1778272B1 (de)	2011-02-09
ES2359925T3 (es)	2011-05-30
RU2007105354A (ru)	2008-09-10
AU2005261868B2 (en)	2009-01-15
MX2007000503A (es)	2007-03-08
WO2006005610A1 (en)	2006-01-19
EP1778272A1 (de)	2007-05-02
US20080138316A1 (en)	2008-06-12
BRPI0513370A (pt)	2008-05-06
KR20070036175A (ko)	2007-04-02
US7671017B2 (en)	2010-03-02
AU2005261868A1 (en)	2006-01-19
PL1778272T3 (pl)	2011-07-29
CA2573207C (en)	2013-04-16
RU2394589C2 (ru)	2010-07-20
DE602005026294D1 (de)	2011-03-24
CA2573207A1 (en)	2006-01-19
CN1984671A (zh)	2007-06-20

Legal Events

Date

Code

Title

Description

2011-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1778272

Country of ref document: EP

Publication	Publication Date	Title
DE602005026294D1 (de)	2011-03-24	Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
ATE490778T1 (de)	2010-12-15	Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
EA200700243A1 (ru)	2007-08-31	Способы лечения гепатита с
ATE525070T1 (de)	2011-10-15	Silbininkomponente zur behandlung von hepatitis
DE602004028841D1 (de)	2010-10-07	Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
ATE475423T1 (de)	2010-08-15	Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen
NO20073632L (no)	2007-09-17	Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
AR021876A1 (es)	2002-08-07	Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
WO2006033995A3 (en)	2006-06-01	Thiazolidin-4-ones having anti-hepatitis b activity
AR045870A1 (es)	2005-11-16	Terapia de combinacion para la infeccion de virus de hepatitis c
MXPA02012443A (es)	2004-09-10	Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
CY1112116T1 (el)	2015-11-04	Μεθοδος θεραπειας ασθενων με ηπατιτιδα c
ATE412666T1 (de)	2008-11-15	Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
MXPA02011969A (es)	2004-09-06	Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
UA103158C2 (ru)	2013-09-25	Конъюгат белок-полимер и способ лечения с его помощью
EA200401618A1 (ru)	2005-06-30	Лечение гепатита с в азиатской популяции подкожным введением бета-интерферона
DK1613340T3 (da)	2010-08-30	Behandling af aspergillus-infektioner med thymosin alfa 1
DE60235955D1 (de)	2010-05-27	Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
UA90477C2 (ru)	2010-05-11	Способ лечения гепатита с (варианты)
NO20034453D0 (no)	2003-10-03	Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
ATE544453T1 (de)	2012-02-15	Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen
EA200601392A1 (ru)	2006-12-29	Способы и композиции для лечения липодистрофии
ATE237616T1 (de)	2003-05-15	Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv
ATE412423T1 (de)	2008-11-15	Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
MXPA05007901A (es)	2005-09-21	Terapia de combinacion para hcv.